The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
SmalleyR.V., AndersenJ.W., HawkinsM.J.Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med.1992; 327(19): 1336-H.
2.
The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med.1994; 330(12): 820–5.
3.
BajettaE., Di LeoA., ZampinoM.G.Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol.1994; 12(4): 806–11.
4.
GreverM., KopeckyK., FoucarM.K.Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol.1995; 13(4): 974–82.
5.
RomerilK.R., CarterJ.M., GreenG.J.Treatment of hairy cell leukaemia with recombinant alpha interferon. N Z Med J.1989; 102(866): 186–8.
6.
HoffmannR., MullerI., NeuberK.Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cis-platin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha 2a. Br J Cancer.1998; 78(8): 1076–80.
7.
EvansL.M., ItriL.M., CampionM.Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Immunother.1991; 10(1): 39–50.
8.
DowL.W., RaimondiS.C., CulbertS.J.D.P.Response to alphainterferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia. Cancer.1991; 68(8): 1678–84.
9.
PerezJ.E., LacavaJ.A., DominguezM.E.Biomodulation with sequential intravenous IFN-alpha 2b and 5-fluorouracil as second-line treatment in patients with advanced colorectal cancer. J Interferon Cytokine Res.1998; 18(8): 565–9.
10.
RaiK.R., DaveyF., PetersonB.Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: Long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia.1995; 9(7): 1116–20.
